BioGaia Pharma wins the jury’s choice award at Medicon Valley Microbiome Pitch Day
BioGaia Pharma participated in the Medicon Valley Microbiome Pitch Day, an event to showcase research projects and startups in the microbiome field looking for collaboration or investment.
On September 27, nine startups were invited to pitch themselves in front of an esteemed investor jury. BioGaia Pharma and Myco Biotix were the two startups selected for their strong science, experienced teams, and clear business models.
“I want to thank Medicon Valley Alliance, for arranging this important event to drive innovation forward and for bringing together startups in the microbiome field to network and inspire others. We are thankful to the jury for the award, which validates the solidity of our approach to LBP (Live Biotherapeutic Product) development”, says Nigel Titford, CEO BioGaia Pharma.
Medicon Valley Microbiome Pitch Day
To learn more about the event and the other startups involved, click here. The event was recorded. To watch the pitch by BioGaia Pharma, please follow this link and click forward to 3:23:22.
For further information, please contact:
Nigel Titford, CEO BioGaia Pharma
Phone: +46706313361
E-mail: nigel.titford@biogaiapharma.com
About BioGaia Pharma
BioGaia Pharma AB is a subsidiary to BioGaia AB set up in 2017 to select and develop live microbial based pharmaceutical product candidates to address real medical needs. Candidates are selected based on supporting pre-clinical and clinical research. It has two prioritised programs. www.biogaiapharma.com
About BioGaia
BioGaia AB is a Swedish world-leading probiotic company that has been at the forefront of microbiome research for more than 30 years. BioGaia develops, markets and sells probiotic products with documented health benefits. To date, over 200 articles on clinical trials with BioGaia’s probiotic strains have been published. The products are sold by nutrition and pharmaceutical companies in more than 100 countries. The class B share of the Parent Company BioGaia AB is quoted on the Mid Cap segment of Nasdaq Stockholm. www.biogaia.com
Tags: